摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

DL-甲基苯丙胺 | 7632-10-2

中文名称
DL-甲基苯丙胺
中文别名
——
英文名称
methamphetamin
英文别名
DL-Methamphetamine;N-methyl-1-phenylpropan-2-amine
DL-甲基苯丙胺化学式
CAS
7632-10-2
化学式
C10H15N
mdl
——
分子量
149.236
InChiKey
MYWUZJCMWCOHBA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    1

ADMET

毒理性
  • 在妊娠和哺乳期间的影响
◉ 母乳喂养期间使用总结:由于缺乏将甲基苯丙胺作为治疗剂在哺乳期使用的已发表经验,可能更倾向于使用其他药物,特别是在哺乳新生儿或早产儿时。一位专家建议,不应在哺乳母亲中作为治疗剂使用安非他明。 甲基苯丙胺不应被哺乳母亲作为消遣性药物使用,因为它可能会影响她们的判断力和照顾孩子能力。在哺乳母亲滥用甲基苯丙胺后,甲基苯丙胺及其代谢物安非他明可以在母乳和婴儿血清中检测到。然而,由于在给哺乳母亲服用消遣性甲基苯丙胺方面存在伦理考量,这些数据来自随机收集而非控制研究。其他需要考虑的因素包括哺乳婴儿可能出现的阳性尿检,这可能具有法律影响,以及街头毒品可能含有其他有害杂质的可能性。通常不鼓励积极滥用安非他明的母亲进行哺乳。对于在哺乳期间滥用甲基苯丙胺的母亲,建议在最后一次使用后48到100小时不进行哺乳,尽管许多母亲在最后一次使用后平均72小时甲基苯丙胺在母乳中已检测不到。有人建议,在母亲安非他明尿检阴性24小时后,可以恢复哺乳。 ◉ 对哺乳婴儿的影响:一名两个月大的婴儿,其母亲通过鼻腔吸入街头非法甲基苯丙胺进行消遣,哺乳和摄入120到180毫升配方奶后8小时被发现死亡。尸检时婴儿血清中甲基苯丙胺浓度为39微克/升。尽管婴儿的母亲因在哺乳期间使用甲基苯丙胺而被判定为危害儿童安全,但由于婴儿血清中甲基苯丙胺浓度较低以及母亲据称哺乳次数较少,甲基苯丙胺在婴儿死亡中的作用受到质疑。 南澳大利亚政府病理学家报告了一名与母亲同睡的哺乳婴儿的死亡。尸检时在婴儿体内发现了“显著”浓度的甲基苯丙胺,认为母乳中的药物可能是导致死亡的一个潜在因素。这些作者还报告说,在之前12个月以下婴儿的死亡案例中,检测到的甲基苯丙胺及其代谢物安非他明可能部分是通过母乳获得的。新西兰政府病理学家也确认了他们国家类似的发现。 ◉ 对泌乳和母乳的影响:给6名受试者(4名男性和2名女性)单次口服0.2毫克/公斤,最多17.5毫克的d-甲基苯丙胺。在给药后300分钟内,血清催乳素浓度没有变化。 在两篇同一作者的文章中,研究了20名具有正常生理性高催乳素血症的妇女,时间为分娩后第2或第3天。其中8人静脉注射了7.5毫克右旋安非他明,6人注射了15毫克,6人作为对照组注射了静脉生理盐水。7.5毫克剂量使血清催乳素下降了25到32%,与对照组相比差异不显著。15毫克剂量在输液后一段时间显著降低了血清催乳素30到37%。没有提出对乳汁产量的评估。作者还引用了另一项研究的数据,显示20毫克口服剂量的右旋安非他明使产后妇女的血清催乳素持续下降了40%。 一项研究比较了31名甲基苯丙胺依赖受试者和23名非依赖受试者。甲基苯丙胺依赖受试者在戒断后第2天和第30天的血清催乳素浓度升高。这种升高在女性中比男性更明显。在已建立泌乳的母亲中,母体催乳素水平可能不会影响她的哺乳能力。 在一项回顾性澳大利亚研究中,与滥用其他药物的母亲相比,怀孕期间使用静脉安非他明的母亲在出院时更不可能在哺乳新生儿(27%对42%)。这种差异的原因尚未确定。 一项前瞻性、多中心研究跟踪了在产前使用甲基苯丙胺的母亲(n = 204)与未使用的母亲(n = 208)。与未暴露的婴儿相比,暴露于甲基苯丙胺的婴儿表现出吸吮力弱、过度吸吮和更多颤抖。使用甲基苯丙胺的母亲在出院时哺乳婴儿的可能性较低(38%),而不使用甲基苯丙胺的母亲哺乳婴儿的可能性较高(76%)。
◉ Summary of Use during Lactation:Because there is no published experience with methamphetamine as a therapeutic agent during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. One expert recommends that amphetamines not be used therapeutically in nursing mothers. Methamphetamine should not be used as a recreational drug by nursing mothers because it may impair their judgment and childcare abilities. Methamphetamine and its metabolite, amphetamine, are detectable in breastmilk and infant's serum after abuse of methamphetamine by nursing mothers. However, these data are from random collections rather than controlled studies because of ethical considerations in administering recreational methamphetamine to nursing mothers. Other factors to consider are the possibility of positive urine tests in breastfed infants which might have legal implications, and the possibility of other harmful contaminants in street drugs. Breastfeeding is generally discouraged in mothers who are actively abusing amphetamines. In mothers who abuse methamphetamine while nursing, withholding breastfeeding for 48 to 100 hours after the maternal use been recommended, although in many mothers methamphetamine is undetectable in breastmilk after an average of 72 hours from the last use. It has been suggested that breastfeeding can be reinstated 24 hours after a negative maternal urine screen for amphetamines. ◉ Effects in Breastfed Infants:A 2-month-old infant whose mother used illicit street methamphetamine recreationally by nasal inhalation was found dead 8 hours after a small amount of breastfeeding and ingestion of 120 to 180 mL of formula. The infant's serum methamphetamine concentration on autopsy was 39 mcg/L. Although the infant's mother was convicted of child endangerment for the use of methamphetamine during breastfeeding, the role that methamphetamine played in the infant's death has been questioned because of the low infant serum methamphetamine concentration and the mother's alleged minimal breastfeeding. South Australian government pathologists reported the death of a breastfed infant who was co-sleeping with its mother. Methamphetamine was found in a “significant” concentration in the infant on autopsy and the drug in breastmilk was thought to be potentially contributory to the death. These authors also reported that in prior deaths of infants under 12 months of age, detectable methamphetamine and its metabolite, amphetamine, may have been partially obtained via breastmilk. Pathologists from the New Zealand government confirmed similar findings in their country. ◉ Effects on Lactation and Breastmilk:A single oral dose of 0.2 mg/kg to a maximum of 17.5 mg of d-methamphetamine was given to 6 subjects (4 male and 2 female). Serum prolactin concentrations were unchanged over a period of 300 minutes after the dose. In 2 papers by the same authors, 20 women with normal physiologic hyperprolactinemia were studied on days 2 or 3 postpartum. Eight received dextroamphetamine 7.5 mg intravenously, 6 received 15 mg intravenously and 6 who served as controls received intravenous saline. The 7.5 mg dose reduced serum prolactin by 25 to 32% compared to control, but the difference was not statistically significant. The 15 mg dose significantly decreased serum prolactin by 30 to 37% at times after the infusion. No assessment of milk production was presented. The authors also quoted data from another study showing that a 20 mg oral dose of dextroamphetamine produced a sustained suppression of serum prolactin by 40% in postpartum women. A study compared 31 methamphetamine-dependent subject to 23 non-dependent subjects. The serum prolactin concentrations in the methamphetamine-dependent subjects were elevated at days 2 and 30 of abstinence. The elevation was greater in women than in men. The maternal prolactin level in a mother with established lactation may not affect her ability to breastfeed. In a retrospective Australian study, mothers who used intravenous amphetamines during pregnancy were less likely to be breastfeeding their newborn infants at discharge than mothers who abused other drugs (27% vs 42%). The cause of this difference was not determined. A prospective, multicenter study followed mothers who used methamphetamine prenatally (n = 204) to those who did not (n = 208). Infants exposed to methamphetamine exhibited poor suck, excessive suck and more jitteriness compared to nonexposed infants. Mothers who used methamphetamine were less likely to breastfeed their infants (38%) at hospital discharge than those who did not use methamphetamine (76%).
来源:Drugs and Lactation Database (LactMed)

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    参考文献:
    名称:
    制备一些伯和仲的β-环己基烷基胺。
    摘要:
    DOI:
    10.1021/ja01197a039
  • 作为产物:
    描述:
    苯基丙酮盐酸甲酸 作用下, 以 为溶剂, 生成 DL-甲基苯丙胺
    参考文献:
    名称:
    Determination of the Synthetic Origin of Methamphetamine Samples by 2H NMR Spectroscopy
    摘要:
    按照最常见的合成途径制备的甲基苯丙胺样品,经天然丰度氘核磁共振光谱法测定。发现分子各位置的氘含量取决于其合成历史。该技术能提供甲基苯丙胺样品的化学指纹,并能提供追溯起始原料和合成步骤的线索。
    DOI:
    10.1021/ac052105w
  • 作为试剂:
    参考文献:
    名称:
    Senoh, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1951, vol. 71, p. 798
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] MÉTHYLOXAZOLES ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
    申请人:MERCK SHARP & DOHME
    公开号:WO2016089721A1
    公开(公告)日:2016-06-09
    The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及甲基噁唑化合物,其为促进睡眠的受体拮抗剂。本发明还涉及所述化合物在潜在治疗或预防涉及促进睡眠的神经和精神疾病和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及促进睡眠的疾病中的用途。
  • [EN] IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY<br/>[FR] RÉACTIF D'IMIDAZOLIUM POUR SPECTROMÉTRIE DE MASSE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2021234004A1
    公开(公告)日:2021-11-25
    The present invention relates to compounds which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said compounds.
    本发明涉及适用于质谱的化合物,以及利用该化合物进行分析物分子的质谱测定方法。
  • [EN] QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO<br/>[FR] DÉRIVÉS DE QUINAZOLINE, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
    申请人:UNIV EMORY
    公开号:WO2013181135A1
    公开(公告)日:2013-12-05
    The disclosure relates to quinazoline derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to inhibitors of NADPH-oxidases (Nox enzymes) and/or myeloperoxidase.
    该披露涉及喹唑啉衍生物、组合物以及相关方法。在某些实施例中,该披露涉及NADPH-氧化酶(Nox酶)和/或髓过氧化物酶的抑制剂。
  • [EN] IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS IMIDAZOPYRIDINE ET LEURS UTILISATIONS
    申请人:NEOMED INST
    公开号:WO2014117274A1
    公开(公告)日:2014-08-07
    This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.
    这项发明通常涉及取代咪唑吡啶化合物,特别是取代的4-(咪唑[1,2-a]吡啶-2-基)苯甲酰胺化合物及其盐。这项发明还涉及包含这种化合物的药物组合物和试剂盒,以及这种化合物的用途(包括治疗方法和药物制剂等),制备这种化合物的方法,以及用于这些方法的中间体。
  • 1,5-Substituted indol-2-yl amide derivatives
    申请人:Nettekoven Matthias
    公开号:US20070123515A1
    公开(公告)日:2007-05-31
    The present invention relates to compounds of formula I wherein R 1 to R 4 and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
    本发明涉及式I的化合物,其中R1至R4和G如描述和索赔中定义的,并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐